 Mycophenolic Acid
"Mycophenolic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.
| Descriptor ID |
D009173
|
| MeSH Number(s) |
D02.241.081.193.678 D10.251.618
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mycophenolic Acid".
Below are MeSH descriptors whose meaning is more specific than "Mycophenolic Acid".
This graph shows the total number of publications written about "Mycophenolic Acid" by people in this website by year, and whether "Mycophenolic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 | | 1998 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2004 | 4 | 1 | 5 | | 2005 | 3 | 0 | 3 | | 2006 | 4 | 0 | 4 | | 2007 | 2 | 1 | 3 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 3 | 2 | 5 | | 2012 | 1 | 2 | 3 | | 2013 | 3 | 1 | 4 | | 2014 | 5 | 1 | 6 | | 2016 | 3 | 2 | 5 | | 2017 | 3 | 0 | 3 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 3 | 4 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 1 | 1 | 2 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mycophenolic Acid" by people in Profiles.
-
Herman D, Ghazipura M, Barnes H, Macrea M, Knight SL, Silver RM, Montesi SB, Raghu G, Hossain T. Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Jan; 21(1):136-150.
-
Almond CS, Sleeper LA, Rossano JW, Bock MJ, Pahl E, Auerbach S, Lal A, Hollander SA, Miyamoto SD, Castleberry C, Lee J, Barkoff LM, Gonzales S, Klein G, Daly KP. The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score. Am Heart J. 2023 06; 260:100-112.
-
Sura AA, Sun Y, Reddy AK, Rathinam SR, Gonzales JA, Thundikandy R, Vedhanayaki R, Kanakath A, Murugan B, Doan TA, Lim LL, Suhler EB, Al-Dhibi HA, Acharya NR. Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial. Ocul Immunol Inflamm. 2024 Aug; 32(6):955-960.
-
Edwards Mayhew RG, Li T, McCann P, Leslie L, Strong Caldwell A, Palestine AG. Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults. Cochrane Database Syst Rev. 2022 10 31; 10:CD014831.
-
Oreschak K, Saba LM, Rafaels N, Ambardekar AV, Deininger KM, PageII R, Lindenfeld J, Aquilante CL. Variants in mycophenolate and CMV antiviral drug pharmacokinetic and pharmacodynamic genes and leukopenia in heart transplant recipients. J Heart Lung Transplant. 2021 09; 40(9):917-925.
-
Cheung AY, Sarnicola E, Eslani M, Wright E, Goebel J, Hooper DK, Govil A, Kurji KH, Holland EJ. Clinical Outcomes of Allogeneic Ocular Surface Stem Cell Transplantation in Pediatric Patients. Cornea. 2021 Jan; 40(1):54-60.
-
Braun WE, Herlitz L, Li J, Schold J, Poggio E, Stephany B, Fatica R, Nally J, Brown K, Fairchild R, Baldwin W, Goldfarb D, Kiser W, Augustine J, Avery R, Tomford JW, Nakamoto S. Continuous function of 80 primary renal allografts for 30-47 years with maintenance prednisone and azathioprine/mycophenolate mofetil therapy: A clinical mosaic of long-term successes. Clin Transplant. 2021 01; 35(1):e14131.
-
Verbsky JW, Hintermeyer MK, Simpson PM, Feng M, Barbeau J, Rao N, Cool CD, Sosa-Lozano LA, Baruah D, Hammelev E, Busalacchi A, Rymaszewski A, Woodliff J, Chen S, Bausch-Jurken M, Routes JM. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J Allergy Clin Immunol. 2021 02; 147(2):704-712.e17.
-
He C, Lee JS, Cool CD, Wicklund MP, Fischer A. Development of Autoimmune Interstitial Lung Disease in a Patient with Inclusion Body Myositis. Am J Med. 2019 12; 132(12):e854-e855.
-
Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019 Aug; 6(8):e409-e418.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|